TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary
Tóm tắt
Borderline tumors (BOT) of the ovary account for 10% to 20% of ovarian neoplasms. Like ovarian cancer, BOT encompass several different histological subtypes (serous, mucinous, endometrioid, clear cell, transitional cell and mixed) with serous (SBOT) and mucinous (MBOT) the most common. Current hypotheses suggest low-grade serous carcinoma may develop in a stepwise fashion from SBOT whereas the majority of high grade serous carcinomas develop rapidly presumably from inclusion cysts or ovarian surface epithelium. The pathogenesis of mucinous ovarian tumors is still puzzling. Molecular markers could help to better define relationships between such entities. Trefoil factor-3 (TFF3) is an estrogen-regulated gene associated with prognosis in different types of cancer. It has also been included in a recent marker panel predicting subtypes of ovarian carcinoma. We analyzed the expression of TFF3 by immunohistochemistry in a cohort of 137 BOT and its association with histopathological features. Overall expression rate of TFF3 was 21.9%. None of the BOT with serous and endometrioid histology displayed strong TFF3 expression. On the other hand, TFF3 was highly expressed in 61.4% of MBOT cases and 33.3% of BOT with mixed histology (P < 0.001) suggesting a potential function of the protein in that subtypes. Associations of TFF3 expression with FIGO stage and micropapillary pattern were significant in the overall cohort but confounded by their correlation with histological subtypes. The highly specific expression of TFF3 in MBOT may help to further clarify potential relationships of tumors with mucinous histology and warrants further studies.
Tài liệu tham khảo
Shih IM, Kurman RJ (2005) Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 11(20):7273–7279. doi:10.1158/1078-0432.CCR-05-0755
Skirnisdottir I, Garmo H, Wilander E, Holmberg L (2008) Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer 123(8):1897–1901. doi:10.1002/ijc.23724
Morice P, Uzan C, Fauvet R, Gouy S, Duvillard P, Darai E (2012) Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol 13(3):e103–e115. doi:10.1016/S1470-2045(11)70288-1
Hart WR (2005) Borderline epithelial tumors of the ovary. Mod Pathol 18(Suppl 2):S33–S50. doi:10.1038/modpathol.3800307
du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroder W, Munstedt K, Richter B, Kommoss S, Hauptmann S, Arbeitsgmeinschaft Gynakologische Onkologie Study G (2013) Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) study group. Eur J Cancer 49(8):1905–1914. doi:10.1016/j.ejca.2013.01.035
Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C, Chi DS, Barakat RR, Abu-Rustum NR (2011) Risk factors for recurrence of ovarian borderline tumors. Gynecol Oncol 120(3):480–484. doi:10.1016/j.ygyno.2010.11.016
Lenhard MS, Mitterer S, Kumper C, Stieber P, Mayr D, Ditsch N, Friese K, Burges A (2009) Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort. Eur J Obstet Gynecol Reprod Biol 145(2):189–194. doi:10.1016/j.ejogrb.2009.04.031
Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A (2006) Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol 100(1):185–191. doi:10.1016/j.ygyno.2005.09.021
Kaern J, Trope CG, Kristensen GB, Abeler VM, Pettersen EO (1993) DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 3(6):349–358
Ayhan A, Guvendag Guven ES, Guven S, Kucukali T (2005) Recurrence and prognostic factors in borderline ovarian tumors. Gynecol Oncol 98(3):439–445. doi:10.1016/j.ygyno.2005.05.033
Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih Ie M (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95(6):484–486
Seidman JD, Kurman RJ (1996) Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 20(11):1331–1345
Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, Bell DA, Berkowitz RS, Mok SC (2000) Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 156(2):409–417. doi:10.1016/S0002-9440(10)64744-X
Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR (2005) Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 29(6):707–723
Ortiz BH, Ailawadi M, Colitti C, Muto MG, Deavers M, Silva EG, Berkowitz RS, Mok SC, Gershenson DM (2001) Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res 61(19):7264–7267
Emerson RE, Wang M, Liu F, Lawrence WD, Abdul-Karim FW, Cheng L (2007) Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions. Int J Gynecol Pathol 26(4):387–394. doi:10.1097/pgp.0b013e3180336287
Vang R, Shih Ie M, Kurman RJ (2013) Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 62(1):44–58. doi:10.1111/his.12046
Ates Ozdemir D, Usubutun A (2016) PAX2, PAX8 and CDX2 expression in metastatic mucinous, primary ovarian mucinous and Seromucinous tumors and review of the literature. Pathol Oncol Res 22(3):593–599. doi:10.1007/s12253-016-0040-2
Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, Berkowitz RS, Tsao SW (1993) Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53(7):1489–1492
Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, Smith AN, Bali A, Vanden Bergh P, Baron-Hay S, Scott C, Fink D, Hacker NF, Sutherland RL, O'Brien PM (2006) A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer 94(6):904–913. doi:10.1038/sj.bjc.6603003
Lau WH, Pandey V, Kong X, Wang XN, Wu Z, Zhu T, Lobie PE (2015) Trefoil factor-3 (TFF3) stimulates de novo angiogenesis in mammary carcinoma both directly and indirectly via IL-8/CXCR2. PLoS One 10(11):e0141947. doi:10.1371/journal.pone.0141947
Ahmed ARH, Griffiths AB, Tilby MT, Westley BR, May FEB (2012) TFF3 is a normal breast epithelial protein and is associated with differentiated phenotype in early breast cancer but predisposes to invasion and metastasis in advanced disease. Am J Pathol 180(3):904–916. doi:10.1016/j.ajpath.2011.11.022
Perry JK, Kannan N, Grandison PM, Mitchell MD, Lobie PE (2008) Are trefoil factors oncogenic? Trends Endocrinol Metab 19(2):74–81. doi:10.1016/j.tem.2007.10.003
Mhawech-Fauceglia P, Wang D, Samrao D, Liu S, DuPont NC, Pejovic T (2013) Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma. Gynecol Oncol 130(1):174–180. doi:10.1016/j.ygyno.2013.03.030
Emami S, Rodrigues S, Rodrigue CM, Le Floch N, Rivat C, Attoub S, Bruyneel E, Gespach C (2004) Trefoil factor family (TFF) peptides and cancer progression. Peptides 25(5):885–898. doi:10.1016/j.peptides.2003.10.019
Pandey V, Wu ZS, Zhang M, Li R, Zhang J, Zhu T, Lobie PE (2014) Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma. Breast Cancer Res 16(5):429. doi:10.1186/s13058-014-0429-3
Jatoi A, Vierkant RA, Hawthorne KM, Block MS, Ramus SJ, Larson NB, Fridley BL, Goode EL (2016) Clinical and emergent biomarkers and their relationship to the prognosis of ovarian cancer. Oncology 90(2):59–68. doi:10.1159/000442710
Kalloger SE, Kobel M, Leung S, Mehl E, Gao D, Marcon KM, Chow C, Clarke BA, Huntsman DG, Gilks CB (2011) Calculator for ovarian carcinoma subtype prediction. Mod Pathol 24(4):512–521. doi:10.1038/modpathol.2010.215
LM MS, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCIEWGoCD (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16):1180–1184. doi:10.1093/jnci/dji237
Kurman RJ, Carcangiu, M.L., Herrington, C.S., Young, R.H (2014) WHO classification of tumours of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer, vol 6.
Kjellev S (2009) The trefoil factor family - small peptides with multiple functionalities. Cell Mol Life Sci 66(8):1350–1369. doi:10.1007/s00018-008-8646-5
Thim L, Woldike HF, Nielsen PF, Christensen M, Lynch-Devaney K, Podolsky DK (1995) Characterization of human and rat intestinal trefoil factor produced in yeast. Biochemistry 34(14):4757–4764
Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP (2007) Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol Oncol 106(3):461–468. doi:10.1016/j.ygyno.2007.05.009
Kirikoshi H, Katoh M (2002) Expression of TFF1, TFF2 and TFF3 in gastric cancer. Int J Oncol 21(3):655–659
Nowak M, Merz C, von Maessenhausen A, Vogel W, Boehm D, Svensson M, Carlsson J, Andren O, Perner S (2015) Role of trefoil factor-3 peptide (TFF3) in prostate cancer progression. Lab invest 95:248a-248a
Kurman RJ, Shih Ie M (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34(3):433–443. doi:10.1097/PAS.0b013e3181cf3d79
Seidman JD, Khedmati F (2008) Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors. Arch Pathol Lab Med 132(11):1753–1760. doi:10.1043/1543-2165-132.11.1753
Lee KR, Scully RE (2000) Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am J Surg Pathol 24(11):1447–1464
Morito K, Nakamura J, Kitajima Y, Kai K, Tanaka T, Kubo H, Miyake S, Noshiro H (2015) The value of trefoil factor 3 expression in predicting the longterm outcome and early recurrence of colorectal cancer. Int J Oncol 46(2):563–568. doi:10.3892/ijo.2014.2755